Application of Tibetan medicine composition in preparation of medicine for treating or relieving pain
By developing Tibetan medicine compositions of medicinal materials such as mother of pearl, the problem of limited efficacy in traditional treatment of neuralgia and lumbar disc herniation has been solved, effective relief of pain and microcirculation improvement, reducing side effects, and providing a safe and efficient treatment plan.
Patent Information
- Application Number
- CN202411208759.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has problems such as treating neuralgia and lumbar disc herniation, not treating the root cause, having great side effects, and long-term use dependence. Traditional Tibetan medicines have limited efficacy in conservative treatment and are difficult to effectively relieve pain.
Develop a Tibetan medicine composition, including mother of pearl, nutmeg, cardamom, travertine, saffron, clove, chidasazeng and pomegranate seeds, to be made into pills or granules by mixing them for treatment or relief Pain, especially neuralgia and lumbar disc herniation.
The Tibetan medicine composition significantly improves the treatment or relief effect of pain, especially for neuralgia and lumbar disc herniation, improves microcirculation, improves the targeting of the drug, and reduces side effects.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicine, and in particular to use of a Tibetan medicine composition in preparing a medicine for treating or relieving pain. Background Art
[0002] The International Pain Society defines neuralgia as severe pain caused by diseases or injuries of the nervous system. The challenge in treating neuralgia is to find the cause and determine the most effective treatment method based on the pathogenesis. In the past few years, many advances have been made in the pathogenesis of neuralgia, and new treatment methods and clinical trials have emerged. However, neuralgia is currently mostly treated with Western medicine, which also has many disadvantages, such as treating the symptoms but not the root cause, having large side effects, and long-term use will cause dependence.
[0003] Lumbar disc herniation is a common and frequently occurring disease in spinal surgery, accounting for 40% of the total number of clinical low back and leg pain. It is mostly caused by lumbar sprain, which leads to changes in the morphology of the lumbar disc, which in turn leads to rupture of the annulus fibrosus, and the nucleus pulposus breaks through the restriction of the annulus fibrosus, protrudes into the vertebral canal, and even directly compresses the nerve roots, resulting in low back pain accompanied by symptoms such as radiating pain and numbness. Traditional Tibetan medicine has a satisfactory effect in conservative treatment.
[0004] Therefore, giving full play to the advantages of traditional Chinese medicine or Tibetan medicine and developing effective traditional Chinese medicine or Tibetan medicine for the treatment or relief of pain has become an urgent issue that needs to be addressed. Summary of the invention
[0005] Therefore, the object of the present invention is to provide a use of a Tibetan medicine composition in preparing a medicine for treating or relieving pain.
[0006] The invention provides use of a Tibetan medicine composition in preparing a medicine for treating or relieving pain. The Tibetan medicine composition comprises mother-of-pearl, nutmeg, cardamom, tsaoko, travertine, safflower, clove, zhidasazeng, liquorice and pomegranate seeds.
[0007] Furthermore, the pain comprises neuralgia.
[0008] Optionally, the neuralgia comprises sciatica.
[0009] Furthermore, the pain includes back pain or leg pain.
[0010] Furthermore, the pain is caused by sciatic nerve damage or lumbar disc herniation.
[0011] The invention provides use of a Tibetan medicine composition in preparing a medicine for treating or alleviating lumbar disc herniation. The Tibetan medicine composition comprises mother-of-pearl, nutmeg, cardamom, tsaoko, travertine, safflower, clove, zhidasazeng, liquorice and pomegranate seeds.
[0012] Furthermore, in terms of weight, the Tibetan medicine composition includes 45-55 parts of mother-of-pearl, 25-50 parts of nutmeg, 25-45 parts of cardamom, 25-45 parts of amomum villosum, 25-45 parts of travertine, 25-45 parts of safflower, 25-45 parts of cloves, 25-30 parts of ginkgo, 25-30 parts of licorice and 25-30 parts of pomegranate seeds.
[0013] Furthermore, the preparation method of the Tibetan medicine composition includes mixing mother-of-pearl, nutmeg, cardamom, cardamom, travertine, safflower, clove, ghizoma sutchuenensis, liquorice and pomegranate seeds.
[0014] Furthermore, the medicine comprises the Tibetan medicine composition, and optionally one or more pharmaceutically acceptable excipients.
[0015] Furthermore, the pharmaceutically acceptable excipient is selected from adhesives; and / or the dosage form of the drug is pills or granules.
[0016] The binder is a conventional binder in the art, such as water.
[0017] Furthermore, the preparation method of the medicine includes weighing mother-of-pearl, nutmeg, cardamom, cardamom, travertine, safflower, cloves, shidasazine, licorice and pomegranate seeds according to selected weight proportions, mixing them and using water as a binder to form pills or granules.
[0018] The technical solution of the present invention has the following advantages:
[0019] The present invention provides a new use of a Tibetan medicine composition, wherein the Tibetan medicine composition is composed of "six good medicines" with other multiple medicinal flavors added thereto, and the "six good medicines" refer to six kinds of medicinal materials: travertine, safflower, cloves, nutmeg, cardamom, and tsaoko. Among the "six good medicines", nutmeg is a good medicine for the heart, cloves are a good medicine for the meridians, cardamom is a good medicine for the kidneys, tsaoko is a good medicine for the spleen, safflower is a good medicine for the liver, and travertine is a good medicine for the lungs. The main drugs in the formula are mother-of-pearl, gidara and licorice, which improve the body's absorption of nutrients and improve the effect of microcirculation. The use of "pomegranate seeds" and "gidara" takes into account both cold and heat, and improves the targeting of drugs to nerves. Studies have found that the Tibetan medicine composition of the present invention can play an active therapeutic or relieving role in pain (especially neuralgia) and lumbar disc herniation. DETAILED DESCRIPTION
[0020] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0021] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.
[0022] Example 1
[0023] The Tibetan medicine composition of this embodiment includes the following raw materials:
[0024] 50g mother of pearl, 25g nutmeg, 25g cardamom, 25g grass fruit, 25g travertine, 25g safflower, 25g cloves, 25g shidasa, 25g licorice, and 25g pomegranate seeds.
[0025] This embodiment also provides a Bawei Ruyi Pill, comprising the above Tibetan medicine composition. Preparation method: crush the above raw materials into fine powder, sieve, mix, soak with water, dry, and make pills.
[0026] Example 2
[0027] The Tibetan medicine composition of this embodiment includes the following raw materials:
[0028] 50g mother of pearl, 45g nutmeg, 45g cardamom, 45g grass fruit, 45g travertine, 45g safflower, 45g cloves, 30g shidasazeng, 30g licorice, and 30g pomegranate seeds.
[0029] The pharmaceutical composition of this embodiment is prepared into granules according to conventional processes.
[0030] Experimental Example 1 Treatment of neuralgia model by the Tibetan medicine composition of the present invention
[0031] 1. Experimental animals and preparation of oral drug solutions
[0032] 40 SPF SD rats (half male and half female) with a body weight of (200-250) g were selected. The experimental rats were kept under the following conditions: temperature 22-24°C, humidity 40%-60%, lighting for 12 hours per day, free access to food, and the experiment was carried out after 7 days of adaptive feeding.
[0033] Preparation of the test drug solution: The pills of Example 1 of the present invention (referred to as "Bawei Ruyi Pills") were ground and dissolved in drinking water to prepare a test drug solution containing 10 mg of the crude drug per ml.
[0034] 2. Model building
[0035] After adaptive feeding, rats were randomly divided into a modeling group and a sham operation group. The modeling group was anesthetized by intraperitoneal injection of 1% pentobarbital (40 mg / kg), and then fixed on the operating table in a prone position. An incision was made in the posterolateral femoral shaft of the right hind thigh to expose the sciatic nerve trunk and its distal branches, which were semi-permeatedly ligated with 6-0 silk thread to construct a sciatic nerve injury model. In the sham operation group, only the sciatic nerve and its branches were exposed without ligation.
[0036] 3. Grouped medication
[0037] The rats with successful modeling were divided into two groups using a random number table method: a model group and a Bawei Ruyi group. Drug administration began on the second day of modeling, and the sham operation group and the model group were given an equal volume of saline by gavage. The Bawei Ruyi group was given the test drug solution by gavage, with a dose of 0.2 g crude drug / kg, a volume of 20 ml / kg, and a frequency of twice a day. All three groups of rats were gavaged for 14 consecutive days.
[0038] 4. Experimental methods
[0039] Pain behavior tests were performed before modeling, 3, 7, and 14 days after modeling, and 6 rats were randomly selected from each group for testing. Before behavioral testing, rats were placed in a transparent glass box to adapt to the environment for 10 minutes. When testing the mechanical withdrawal threshold (MWT), the metal probe vertically stimulated the center of the sole of the bilateral hind paws, and the analgesic instrument automatically recorded the minimum stimulation intensity for the rat to produce rapid withdrawal, licking, and other withdrawal reflexes. The average value of three repeated measurements was taken as the MWT. When testing the thermal withdrawal latency (TWL), the analgesic instrument was turned on and the temperature was set to 55°C. When the temperature of the hot plate reached the set value, the rat was placed on the plate. When the rat showed a withdrawal or licking reaction on the affected side, the timing was stopped and the time was recorded. The average value of three repeated measurements was taken as the TWL.
[0040] 5. Experimental results
[0041] The results of pain behavior test of rats in each group were compared (see Table 1 and Table 2). The MWT and TWL values of rats in the model group and the Bawei Ruyi group were reduced to the lowest value 3 days after surgery. Compared with the sham operation group, the MWT and TWL values of rats in the model group at each time point after surgery were significantly decreased (P<0.01); compared with the model group, the MWT and TWL values of rats in the Bawei Ruyi group were significantly prolonged at 14 days after surgery (P<0.01). It shows that the Tibetan medicine composition of the present invention has a therapeutic or alleviating effect on the pain of the rat model of neuralgia.
[0042] Table 1 Comparison of MWT indexes of rats in each group (n=6)
[0043] Group Preoperative 3 days after surgery 7 days after surgery 14 days after surgery Sham operation group 61.45±4.12 60.25±2.01 63.05±2.80 58.90±2.15 Model Group 57.89±5.67 12.75±1.47** 12.60±0.75** 15.80±1.20** Eight-flavor Ruyi Group 61.50±2.90 14.97±0.92 17.45±1.23△△ 27.30±1.56△△
[0044] Table 2 Comparison of MWT indexes of rats in each group (n=6)
[0045] Group Preoperative 3 days after surgery 7 days after surgery 14 days after surgery Sham operation group 16.05±1.05 15.55±1.10 15.10±0.70 16.20±1.30 Model Group 16.47±0.80 7.32±0.25** 7.45±0.40** 6.05±0.45** Eight-flavor Ruyi Group 16.88±1.20 10.25±0.75 11.55±1.00△△ 14.50±0.50△△
[0046] Compared with the sham operation group, *P<0.05, **P<0.01; compared with the model group, △P<0.05, △△P<0.01.
[0047] Experimental Example 2: Clinical Experiment on Improving the Function of Lumbar Disc Herniation
[0048] 1.1 General Information
[0049] From April to December 2023, a total of 45 cases of lumbar disc herniation were treated, with an age range of 29 to 80 years; the course of disease was more than 5 years.
[0050] 1.2 Diagnostic criteria
[0051] 1. Disease diagnosis
[0052] Refer to the "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" issued by the TCM Industry Standard of the People's Republic of China in 1994. 1. Most patients have a history of lumbar trauma, chronic strain or cold and dampness. Most patients have a history of chronic low back pain before the onset of the disease. 2. It often occurs in young and middle-aged people. 3. Low back pain radiates to the buttocks and lower limbs, and the pain worsens when the abdominal pressure increases (such as coughing and sneezing). 4. Scoliosis, disappearance of the physiological curvature of the lumbar spine, tenderness beside the vertebrae at the lesion site, and radiate to the lower limbs, and limited lumbar movement. 5. The affected nerve innervation area of the lower limbs has hypersensitivity or dullness, and muscle atrophy may occur in patients with a long course of disease. Straight leg raising or strengthening test is positive, knee and heel reflexes are weakened or disappeared, and thumb dorsiflexion may be weakened. 6. X-ray examination: scoliosis, shallow lumbar physiological lordosis, the diseased intervertebral disc may be narrowed, and there is osteophyte hyperplasia on the corresponding edge. CT or MRI examination can show the location and degree of intervertebral disc herniation.
[0053] 2. Disease staging
[0054] 1. Acute stage: severe pain in waist and legs, obvious limitation of movement, inability to stand or walk, muscle cramps. 2. Remission stage: pain in waist and legs is relieved, movement is improved, but there is still pain and intolerance. 3. Recovery stage: symptoms of waist and leg disease basically disappear, but there is weakness in waist and legs, inability to stand or walk for a long time.
[0055] (III) Syndrome Diagnosis
[0056] 1. Blood stasis and qi stagnation syndrome: recent history of waist trauma, severe waist and leg pain, fixed pain, stabbing pain, waist stiffness, difficulty in pitching and stretching, pain refusing to press, dark purple tongue, or ecchymosis, thin white or thin yellow tongue coating, deep and astringent pulse or stringy pulse. 2. Cold and dampness arthralgia syndrome: cold and heavy pain in the waist and legs, difficulty in turning, fixed pain, no relief or even worsening even when lying still, lighter during the day and heavier at night, increased pain in cold, reduced by heat, fat and pale tongue, greasy white coating, stringy, slow or deep and tight pulse. 3. Damp-heat arthralgia syndrome: pain in the waist, tendons and legs, pain accompanied by heat, or red and swollen limbs, thirst without desire to drink, yellow and greasy coating, moist and rapid or slippery pulse. 4. Liver and kidney deficiency syndrome: lingering waist and leg pain for a long time, repeated attacks, fatigue, intolerance to fatigue, aggravated by fatigue, relieved by lying down; including liver and kidney yin deficiency and liver and kidney yang deficiency syndrome. Symptoms of Yin deficiency include: restlessness and insomnia, bitter mouth and dry throat, red tongue with little fluid, and stringy and thin pulse. Symptoms of Yang deficiency include: cold limbs, cold body and fear of cold, muscle and vein cramps, pale and fat tongue, and deep and thin pulse.
[0057] 1.3 Inclusion criteria
[0058] Inclusion criteria: (1) patients with lumbar disc herniation; (2) aged 25-70 years, regardless of gender; (3) voluntary participation and consent to follow-up.
[0059] Exclusion criteria: (1) not meeting the criteria for lumbar disc herniation; having severe primary cardiovascular disease, liver disease, kidney disease, hematological disease, or other serious diseases that affect their survival; (2) being younger than 25 years old; (3) being allergic to therapeutic drugs; (4) being a mental patient.
[0060] 1.4 Trial drugs and treatments
[0061] Medication method: Patients take the pills prepared in Example 1 orally to treat lumbar intervertebral herniation, with 15 days as one course of treatment, once in the morning and evening every day, 2g each time, for one course of treatment.
[0062] 1.5 Observation indicators and evaluation methods
[0063] With reference to the Japanese Orthopaedic Association scores (JOA scores), lumbar disc herniation was scored in 10 aspects, including the degree of low back pain and leg pain, and personal life management, before treatment and after one course of medication according to the scoring criteria shown in Table 3. The total scores of all patients were calculated and recorded as the scores before and after medication.
[0064] The occurrence rate and remission rate were calculated as follows: the occurrence rate of a certain symptom = the number of patients with the symptom score ≥ 1 before medication / total number of people * 100%; the remission rate of a certain symptom % = (number of cured people + number of improved people) / total number of people * 100%. Among them, cure: clinical symptoms completely disappear, that is, the score after medication is lower than before medication and the score after medication is 0. Improvement: clinical symptoms basically disappear or alleviate to varying degrees, that is, the score after medication is lower than before medication and the score after medication is not 0. Ineffective: clinical symptoms are not alleviated, and there is no change in the score after medication compared with before medication.
[0065] Table 3 Lumbar disc herniation scoring table
[0066]
[0067]
[0068] 1.6 Statistical analysis
[0069] SPAS statistical software was used to perform statistical analysis on the scores of patients before and after medication. All statistical tests were two-sided, and P ≤ 0.05 was used as the standard for statistical significance of the differences tested (unless otherwise specified).
[0070] 2 Experimental results
[0071] Table 4 Test results
[0072]
[0073]
[0074] As can be seen from the above table, compared with before taking the medicine, after taking the medicine of the present invention, the patient's low back pain, leg pain, personal life and management conditions are significantly improved. The medicine of the present invention can treat or relieve the pain of lumbar disc herniation.
[0075] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. Use of a Tibetan medicine composition in preparing a medicine for treating or relieving pain, characterized in that: The Tibetan medicine composition includes mother of pearl, nutmeg, cardamom, cardamom, tsaoko, travertine, safflower, clove, zhidasazeng, liquorice and pomegranate seeds.
2. The use according to claim 1, characterized in that The pain includes neuralgia.
3. The use according to claim 2, characterized in that: The pain includes back pain or leg pain.
4. The use according to claim 1, characterized in that The pain is caused by sciatic nerve damage or lumbar disc herniation.
5. Use of a Tibetan medicine composition in preparing a medicine for treating or alleviating lumbar disc herniation, characterized in that: The Tibetan medicine composition includes mother of pearl, nutmeg, cardamom, cardamom, tsaoko, travertine, safflower, clove, zhidasazeng, liquorice and pomegranate seeds.
6. The use according to any one of claims 1 to 5, characterized in that: According to the weight parts, the Tibetan medicine composition includes 45-55 parts of mother-of-pearl, 25-50 parts of nutmeg, 25-45 parts of cardamom, 25-45 parts of amomum villosum, 25-45 parts of travertine, 25-45 parts of safflower, 25-45 parts of cloves, 25-30 parts of shidasazeng, 25-30 parts of licorice and 25-30 parts of pomegranate seeds.
7. The use according to any one of claims 1 to 6, characterized in that: The preparation method of the Tibetan medicine composition comprises the following steps: mixing mother-of-pearl, nutmeg, cardamom, tsaoko, travertine, safflower, clove, zhidasazeng, liquorice and pomegranate seeds.
8. The use according to any one of claims 1 to 7, characterized in that: The medicine comprises the Tibetan medicine composition and optionally one or more pharmaceutically acceptable excipients.
9. The use according to claim 8, characterized in that The pharmaceutically acceptable excipients include a binder; and / or the drug is in the form of a pill or a granule.
10. The use according to claim 9, characterized in that The preparation method of the medicine comprises the following steps: weighing mother-of-pearl, nutmeg, cardamom, tsaoko, travertine, safflower, clove, shidasazeng, liquorice and pomegranate seeds according to selected weight proportions, mixing them and preparing them into pills or granules with water as a binder.
Citation Information
Patent Citations
Application of Ruyizhenbao pill / tablet to treatment of vascular dementia
CN102908572A
Application of Tibetan medicine composition in preparation of medicine for preventing or treating autism spectrum disorder
CN118161582A
Nano 25-component pearl medicine and its preparing process
CN1365720A
